Bigbear Pharmaceutical·Medication Guide

• Trametinib (TAFINLAR) Drug Guide

  The U.S. Food and Drug Administration (FDA) has approved dabrafenib (TAFINLAR®, Novartis Pharmaceuticals Corp.) and trametinib (MEKINIST®, Novartis Ph···【Read More】

  Update: 2026-04-02Source: Haiou HealthViews: 112

• First-in-Class Combination Therapy for Advanced HR-Positive Breast Cancer! Truqap + Fulvestrant Appr

  According to the American Cancer Society, breast cancer is the most common cancer among women in the United States. HR-positive breast cancer (express···【Read More】

  Update: 2026-04-02Source: Haiou HealthViews: 102

• Promising Efficacy Demonstrated for Truqap Combination Therapy in Phase 3 Trial for the Treatment of

  AstraZeneca recently announced positive results from the Phase 3 CAPItello-281 clinical trial. The analysis showed that in patients with PTEN-deficien···【Read More】

  Update: 2026-04-02Source: Haiou HealthViews: 101

• Capivasertib in Combination with Faslodex Demonstrates Significant Efficacy in Phase 3 Trial for HR-

  AstraZeneca recently announced positive top-line results from the Phase 3 CAPItello-291 trial. This global, double-blind, randomized Phase 3 study for···【Read More】

  Update: 2026-04-02Source: Haiou HealthViews: 104

• What other medications may interact with belzutifan?

  Belzutifan may be affected by other medications, including prescription drugs, over-the-counter products, vitamins, and herbal supplements. Inform you···【Read More】

  Update: 2026-04-02Source: Haiou HealthViews: 115

• What should I avoid while taking belzutifan?

  Adhere to your healthcare provider’s guidance regarding any limitations on food, drink, or daily activities.【Read More】

  Update: 2026-04-02Source: Haiou HealthViews: 120

• What if I take too much (overdose) of Belzutifan?

  Seek immediate emergency medical assistance or contact the Poison Control Helpline.【Read More】

  Update: 2026-04-02Source: Haiou HealthViews: 116

• What if I miss a dose of Belzutifan?

  Take the missed dose as soon as you remember on the same day. Continue with your next dose at the usual scheduled time and maintain your once-daily do···【Read More】

  Update: 2026-04-02Source: Haiou HealthViews: 117

• Indications for Belzutifan:

  Belzutifan has shown objective response in the treatment of adult patients with VHL-related tumors, certain advanced RCC, and PPGL aged 12 years and o···【Read More】

  Update: 2026-04-01Source: Haiou HealthViews: 133

• Side Effects of Belzutifan

  Because Belzutifan's mechanism of action involves regulating oxygen-sensing pathways in the tumor microenvironment, it may have a wide-ranging imp···【Read More】

  Update: 2026-04-01Source: Haiou HealthViews: 137

• Belzutifan Dosage Guidelines

  Belzutifan, a novel anti-tumor drug targeting HIF-2α, requires strict adherence to individualized treatment principles to control disease progression ···【Read More】

  Update: 2026-04-01Source: Haiou HealthViews: 137

• Belzutifan cost, Welireg price per month

  Belzutifan is a targeted therapy drug used to treat specific cancers, and its price varies significantly depending on factors such as region, dosage, ···【Read More】

  Update: 2026-04-01Source: Haiou HealthViews: 138

• FDA Approves Welireg for Treatment of Advanced Pheochromocytoma and Paraganglioma

  On May 14, 2025, Merck announced that the U.S. Food and Drug Administration (FDA) has approved Welireg (belzutifan) for the treatment of adult and ped···【Read More】

  Update: 2026-04-01Source: Haiou HealthViews: 120

• HIF-2α Inhibitor Welireg Approved by FDA for Advanced Renal Cell Carcinoma

  On December 15, the U.S. Food and Drug Administration (FDA) approved Merck's oral treatment Welireg (belzutifan) for the treatment of adult patien···【Read More】

  Update: 2026-04-01Source: Haiou HealthViews: 149

• What are the common adverse reactions of bezotiva?

  On March 16, 2021, Merck announced that the U.S. FDA approved Welireg (belzutifan) for the treatment of adult patients with renal cell carcinoma (RCC)···【Read More】

  Update: 2026-04-01Source: Haiou HealthViews: 122